These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://aliviahtei217166.mybuzzblog.com/19118281/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide